A new systematic review reveals promising results for oncolytic viral therapy in treating nonmelanoma skin cancers and ...

Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. <li /> SNGX's HyBryte is a ...

Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

ST-001, an intravenous nanoformulation of fenretinide, will be evaluated in a phase 1a/1b small cell lung cancer trial.

BI-1808 as monotherapy in Cutaneous T Cell Lymphoma (CTCL) will be presented at the 16th Annual T-Cell Lymphoma Forum held March 20-22, 2025 in La Jolla, California. The data, previously disclosed ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal ...

T-cell lymphomas include a number of subtypes of T cell-derived non-Hodgkins's lymphoma, including cutaneous T-cell lymphoma (CTCL). CTCL is a rare and aggressive form that originates in T ...

FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK ...

AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on ...

Citius Oncology, Inc.’s CTOR share price has dipped by 10.12%, which has investors questioning if this is right time to buy.